Exousia Bio, Inc.
LMMY· OTC
LMMYExousia Bio, Inc.
Filed Jan 10, 2025 · 10-Q · 41 days after period end · 0001683168-25-000221
| Metric | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|
| Revenue | $0.00 | $3.88K | $0.00 |
| Net Income | $80.13K | -$3.57K | -$8.41K |
| EPS Diluted | $0.01 | $0.00 | $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Exousia Bio, Inc. · CIK 1939937 · Engraved from SEC EDGAR
ended Nov 30, 2024 · filed Jan 10, 2025 · 41 d after period end
